Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)
Bristol Myers Squibb (CELG-RI) reported Construction in Progress of $1.5 billion for Q1 2026, down 6.94% year-over-year from $1.7 billion in Q1 2025, and down 4.82% quarter-over-quarter from $1.6 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 12 years of Construction in Progress data on file, last reported at $1.5 billion in Q1 2026.
- Construction in Progress for Q1 2026 came in at $1.5 billion, down 6.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 6.94% YoY), and the FY2025 annual result was $1.6 billion, up 6.16% from the prior year.
- Construction in Progress fell to $1.5 billion in Q1 2026 per CELG-RI's latest filing, from $1.6 billion in the prior quarter.
- Over five years, Construction in Progress peaked at $1.8 billion in Q2 2025 and troughed at $800.0 million in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Construction in Progress.
- The sharpest annual moves came in 2022 and 2026: Construction in Progress soared 54.14% in 2022, then declined 6.94% in 2026.
- A 5-year view of Construction in Progress shows it stood at $1.1 billion in 2022, then grew by 2.09% to $1.1 billion in 2023, then jumped by 41.86% to $1.5 billion in 2024, then grew by 6.16% to $1.6 billion in 2025, then fell by 4.82% to $1.5 billion in 2026.
- Business Quant data shows CELG-RI's Construction in Progress at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 1.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.62 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 973.00 Mn |
| Jun 30, 2022 | 850.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 764.00 Mn |
| Sep 30, 2021 | 695.00 Mn |
| Jun 30, 2021 | 565.00 Mn |